According to a recent LinkedIn post from TandemStride, clinical leaders at the company’s Future of Survivorship event emphasized a strong need for better PTSD assessment tools, specifically prioritizing the PCL-5 measure. The same discussion reportedly highlighted demand for screening around social determinants of health, anxiety (GAD-7), depression (PHQ-9), alcohol use, and pediatric populations.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post suggests TandemStride may focus future product development on behavioral health and post-discharge assessment capabilities that address these identified gaps. For investors, such a roadmap could position the company more deeply in outcomes-driven, value-based care workflows, potentially enhancing its relevance to health systems seeking comprehensive survivorship and mental health monitoring solutions.